// App-Quantinova.ai

7037 : The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.

Researchers

Presenter

  • Tim H. Brmmendorf

Principal Investigators

  • Jorge E. Cortes

  • Lambert Busque

  • Carlo Gambacorti-Passerini

  • Leif Stenke

  • Andrea Viqueira

  • Eric Leip

  • Simon Purcell

  • Michael W Deininger

Medical Centers

  • Uniklinik RWTH Aachen, Aachen, Germany

  • Georgia Cancer Center, Augusta, GA.

  • Université de Montréal, Montreal

  • Canada.

  • University of Milano-Bicocca, Monza, Italy

  • Karolinska Institutet, Stockholm, Sweden

  • Pfizer Spain, Madrid, Spain

  • Pfizer Inc., Cambridge, MA

  • Pfizer Ltd, London, United Kingdom

  • University of Utah Medical Center, Salt Lake City, UT

Locations

  • Germany

  • United States

  • Canada

  • Italy

  • Sweden

  • Spain

  • United Kingdom

Companies

  • PharmAbcine Inc.

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Ischemia Modified Albumin

  • Body mass index

Drug/Treatment

  • Bosutinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • N/A

Study Id's

  • NCT02130557

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved